metyrapone has been researched along with Fibromyalgia in 1 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
Fibromyalgia: A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metyrapone (30 mg/kg) was administered orally at 23:00 h and blood was sampled at 08:30 h the following morning for 11-deoxycortisol." | 6.71 | Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. ( Ates, F; Calis, M; Demir, H; Durak, AC; Gökçe, C; Izgi, HB; Kelestimur, F; Kirnap, M; Sofuoglu, S; Tutus, A; Ulker, S, 2004) |
| "Metyrapone (30 mg/kg) was administered orally at 23:00 h and blood was sampled at 08:30 h the following morning for 11-deoxycortisol." | 2.71 | Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. ( Ates, F; Calis, M; Demir, H; Durak, AC; Gökçe, C; Izgi, HB; Kelestimur, F; Kirnap, M; Sofuoglu, S; Tutus, A; Ulker, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calis, M | 1 |
| Gökçe, C | 1 |
| Ates, F | 1 |
| Ulker, S | 1 |
| Izgi, HB | 1 |
| Demir, H | 1 |
| Kirnap, M | 1 |
| Sofuoglu, S | 1 |
| Durak, AC | 1 |
| Tutus, A | 1 |
| Kelestimur, F | 1 |
1 trial available for metyrapone and Fibromyalgia
| Article | Year |
|---|---|
Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome.
Topics: Adrenal Glands; Adrenal Insufficiency; Adrenocorticotropic Hormone; Cortodoxone; Female; Fibromyalgi | 2004 |